ADAP
Price
$0.28
Change
-$0.01 (-3.45%)
Updated
Jun 6 closing price
Capitalization
75.78M
59 days until earnings call
AKBA
Price
$3.97
Change
+$0.28 (+7.59%)
Updated
Jun 6 closing price
Capitalization
971.75M
53 days until earnings call
Interact to see
Advertisement

ADAP vs AKBA

Header iconADAP vs AKBA Comparison
Open Charts ADAP vs AKBABanner chart's image
Adaptimmune Therapeutics
Price$0.28
Change-$0.01 (-3.45%)
Volume$873.86K
Capitalization75.78M
Akebia Therapeutics
Price$3.97
Change+$0.28 (+7.59%)
Volume$8.18M
Capitalization971.75M
ADAP vs AKBA Comparison Chart
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. AKBA commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and AKBA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (ADAP: $0.27 vs. AKBA: $2.88)
Brand notoriety: ADAP and AKBA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 15% vs. AKBA: 82%
Market capitalization -- ADAP: $75.78M vs. AKBA: $971.75M
ADAP [@Biotechnology] is valued at $75.78M. AKBA’s [@Biotechnology] market capitalization is $971.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileAKBA’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • AKBA’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 5 TA indicator(s) are bullish while AKBA’s TA Score has 3 bullish TA indicator(s).

  • ADAP’s TA Score: 5 bullish, 3 bearish.
  • AKBA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than AKBA.

Price Growth

ADAP (@Biotechnology) experienced а -1.42% price change this week, while AKBA (@Biotechnology) price change was +2.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 06, 2025.

AKBA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($972M) has a higher market cap than ADAP($75.8M). AKBA YTD gains are higher at: 51.579 vs. ADAP (-49.675). AKBA has higher annual earnings (EBITDA): -13.72M vs. ADAP (-55.9M). ADAP has more cash in the bank: 186M vs. AKBA (51.9M). AKBA has less debt than ADAP: AKBA (47.6M) vs ADAP (74.5M). ADAP has higher revenues than AKBA: ADAP (175M) vs AKBA (160M).
ADAPAKBAADAP / AKBA
Capitalization75.8M972M8%
EBITDA-55.9M-13.72M407%
Gain YTD-49.67551.579-96%
P/E RatioN/AN/A-
Revenue175M160M109%
Total Cash186M51.9M358%
Total Debt74.5M47.6M157%
FUNDAMENTALS RATINGS
ADAP vs AKBA: Fundamental Ratings
ADAP
AKBA
OUTLOOK RATING
1..100
218
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6535
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (54) in the Biotechnology industry is in the same range as AKBA (75). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's SMR Rating (97) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (35) in the Biotechnology industry is in the same range as ADAP (65). This means that AKBA’s stock grew similarly to ADAP’s over the last 12 months.

AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ADAP (100). This means that AKBA’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPAKBA
RSI
ODDS (%)
N/A
Bearish Trend 12 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 12 days ago
83%
Bearish Trend 12 days ago
78%
Momentum
ODDS (%)
Bullish Trend 12 days ago
81%
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
83%
Bullish Trend 12 days ago
84%
Advances
ODDS (%)
Bullish Trend 13 days ago
76%
Bullish Trend 13 days ago
85%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend 28 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
86%
Aroon
ODDS (%)
Bullish Trend 12 days ago
86%
Bullish Trend 12 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-3.28%
AKBA - ADAP
41%
Loosely correlated
-1.37%
AUTL - ADAP
33%
Poorly correlated
+5.10%
ELVN - ADAP
33%
Poorly correlated
+0.50%
ATXS - ADAP
33%
Poorly correlated
+6.85%
CSLLY - ADAP
32%
Poorly correlated
-1.50%
More

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-1.37%
XERS - AKBA
42%
Loosely correlated
-1.04%
ADAP - AKBA
41%
Loosely correlated
-3.28%
ATOS - AKBA
40%
Loosely correlated
-3.13%
ABOS - AKBA
40%
Loosely correlated
N/A
FHTX - AKBA
39%
Loosely correlated
+6.17%
More